These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11926751)

  • 1. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation.
    Zamora MR
    Transpl Infect Dis; 2001; 3 Suppl 2():49-56. PubMed ID: 11926751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis with ganciclovir and cytomegalovirus immune globulin in liver and intestinal transplantation.
    Tzakis AG
    Transpl Infect Dis; 2001; 3 Suppl 2():35-9. PubMed ID: 11926748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.
    Weill D; Lock BJ; Wewers DL; Young KR; Zorn GL; Early L; Kirklin JK; McGiffin DC
    Am J Transplant; 2003 Apr; 3(4):492-6. PubMed ID: 12694074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
    Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.
    Ranganathan K; Worley S; Michaels MG; Arrigan S; Aurora P; Ballmann M; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Mallory GB; Mogayzel PJ; Parakininkas D; Solomon M; Visner G; Sweet SC; Faro A; Danziger-Isakov L
    J Heart Lung Transplant; 2009 Oct; 28(10):1050-6. PubMed ID: 19782286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
    Kruger RM; Paranjothi S; Storch GA; Lynch JP; Trulock EP
    J Heart Lung Transplant; 2003 Jul; 22(7):754-63. PubMed ID: 12873543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
    Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cytomegalovirus in cardiac allograft vasculopathy.
    Weill D
    Transpl Infect Dis; 2001; 3 Suppl 2():44-8. PubMed ID: 11926750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
    Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
    Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
    Grossi P; Mohacsi P; Szabolcs Z; Potena L
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
    Valantine HA; Luikart H; Doyle R; Theodore J; Hunt S; Oyer P; Robbins R; Berry G; Reitz B
    Transplantation; 2001 Nov; 72(10):1647-52. PubMed ID: 11726825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.
    Snydman DR
    Transpl Infect Dis; 2001; 3 Suppl 2():6-13. PubMed ID: 11926753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
    Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
    Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.